Business Context and Reporting Period
This Form 8-K is filed by Artelo Biosciences, Inc. (Nasdaq: ARTL) on January 14, 2026. The report addresses a notice of non-compliance with Nasdaq Listing Rule 5620(a) regarding the failure to hold an annual meeting of stockholders within the required timeframe. The Company's 2025 Annual Meeting, originally scheduled for December 31, 2025, was adjourned due to a lack of quorum and is rescheduled for January 30, 2026.
Key Financial Metrics
This filing is a current report regarding corporate governance and listing status; it does not contain financial statements, revenue, profit, cash flow, or margin data for the reporting period. The filing references a previously disclosed deficiency regarding the minimum stockholders' equity requirement under Listing Rule 5550(b)(1), noting a shortfall of $2.5 million.
Material Changes
- Listing Status: The Company received a formal notice from Nasdaq indicating non-compliance with the Annual Meeting Rule, which could serve as an additional basis for delisting.
- Meeting Status: The 2025 Annual Meeting was adjourned from December 31, 2025, to January 30, 2026, to allow additional time for stockholder voting.
- Regulatory Action: The Company has submitted a plan of compliance to a Nasdaq Hearing Panel addressing both the Annual Meeting deficiency and the previously disclosed equity deficiency.
Outlook, Risks, and Management Commentary
Management intends to take all reasonable measures to regain compliance with Nasdaq Listing Rules. The Company acknowledges that there is no assurance it will successfully regain compliance or that its appeal regarding the equity deficiency will be successful. The Nasdaq Notice states that the Company's common stock will continue to be listed and traded pending the outcome of the hearing process and any potential extension periods granted by the Panel.
Investor Verification Checklist
- Verify the outcome of the rescheduled Annual Meeting on January 30, 2026.
- Monitor the decision of the Nasdaq Hearing Panel regarding the $2.5 million stockholders' equity deficiency.
- Confirm whether the Company receives an extension period to regain compliance with the Annual Meeting Rule.
- Review the definitive proxy statement (filed December 11, 2025) and supplement (filed January 7, 2026) for details on the proposals to be voted upon.